Trial | NCT01033721  Report issue

Title

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration
A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients With Advanced Neovascular Age-Related Macular Degeneration (AMD)

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    13
Palomid 529 is a dual TORC1/2 inhibitor of the PI3K/Akt/mTOR pathway having broad activity in angiogenesis and cellular proliferation. Palomid 529 will be examined to determine if the safety, tolerability and pharmacokinetic profile of single ascending doses when administered intravitreally or subconjunctivally.
Study Started
Jun 30
2010
Primary Completion
Dec 31
2011
Study Completion
Dec 31
2011
Last Update
Sep 24
2012
Estimate

Drug Palomid 529

comparison of different dosages of drug

  • Other names: P529

Criteria 

Inclusion Criteria:

Best corrected visual acuity in the study eye between 20/100 and 20/800 (between 53 and 4 ETDRS letters read), and better or equal to 20/200 (minimum of 34 letters read) in the fellow eye.
Subfoveal choroidal neovascularization (CNV) due to AMD
Total area of the lesion (including blood, neovascularization and scar/atrophy) must be < 12 DA.
Only 1 eye will be treated in the study. If both eyes are eligible, the investigator will select the eye with the most active CNV
Clear ocular media and adequate pupillary dilatation to permit good stereo fundus photography for screening
Intraocular pressure of 21 mm Hg or less
Retinal thickness ≥ 250 μm by OCT, with presence of intraretinal or subretinal fluid

Exclusion Criteria:

Any retinovascular disease or retinal degeneration other than AMD
Serous pigment epithelial detachment without the presence of neovascularization
Previous posterior vitrectomy or retinal surgery
Any periocular infection in the past 4 weeks
Concomitant therapy with anti-VEGF therapies, e.g. Avastin, Lucentis or Macugen, or previous use of these agents within 60 days of screening
Concomitant therapy with intravenous or intravitreous corticosteroids or use within 90 days of screening
Significant media opacities, including cataract, which might interfere with visual acuity, assessment of toxicity, or fundus photography
Cataract surgery in the study eye within 3 months of screening
Intraocular surgery in the study eye within 3 months of screening
Presence of ocular infection in the study eye
Presence of severe myopia (-8 diopters or greater) in the study eye
No Results Posted